Related Experiment Video
Updated: Jan 31, 2026

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
Published on: July 16, 2012
Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets
Nathalie Alazard-Dany1, Solène Denolly2, Bertrand Boson3
1CIRI-Centre International de Recherche en Infectiologie, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, F-69007 Lyon, France. nathalie.alazard-dany@inserm.fr.
Insights
Hepatitis C (HCV) eradication is achievable by 2030 thanks to highly effective direct-acting antivirals (DAAs). This review covers HCV targets, DAA mechanisms, and future inhibitor development for liver disease treatment.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Hepatitis C virus (HCV) infection is a primary cause of liver disease globally, impacting approximately 3% of the population.
- The World Health Organization (WHO) aims for HCV eradication by 2030, driven by advancements in treatment.
Purpose of the Study:
- To provide an overview of the Hepatitis C virus life cycle.
- To describe the functions of molecular targets for current direct-acting antivirals (DAAs).
- To explain the mechanisms of action for existing DAAs and explore potential future inhibitors.
Main Methods:
- Literature review of scientific publications since the 1990s.
- Analysis of the molecular targets and mechanisms of direct-acting antivirals.
- Discussion of research and development in antiviral therapies.
Main Results:
- Direct-acting antivirals (DAAs) developed since the 1990s are highly effective treatments for Hepatitis C.
- Current DAAs target specific proteins essential for the HCV life cycle.
- Significant progress has been made, supporting the WHO's 2030 eradication goal.
Conclusions:
- Novel DAAs represent a major breakthrough in managing and potentially eliminating Hepatitis C virus infection.
- Understanding viral targets and drug mechanisms is crucial for developing next-generation inhibitors.
- Continued research is vital to achieve global HCV eradication.
Abstract:
Hepatitis C infection is the leading cause of liver diseases worldwide and a major health concern that affects an estimated 3% of the global population. Novel therapies available since 2014 and 2017 are very efficient and the WHO considers HCV eradication possible by the year 2030. These treatments are based on the so-called direct acting antivirals (DAAs) that have been developed through research efforts by academia and industry since the 1990s. After a brief overview of the HCV life cycle, we describe here the functions of the different targets of current DAAs, the mode of action of these DAAs and potential future inhibitors.
Related Concept Videos
The Angiosperm Life Cycle
Retrovirus Life Cycles
Controlled-Current Coulometry: Overview
Characteristics of Life
The Citric Acid Cycle: Overview
The citric...
Half-life of a Reaction

